Guidelines update, v40.3
25 June, 2021
Version 40.3 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of several new studies on disease-modifying treatments as well as an added remark to tociluzumab and sarilumab recommendations acknowledging the release of updated results from REMAP-CAP. Remdesivir - one new study comparing remdesivir to standard care in 832 patients with moderate-critical COVID-19 (Ader...